Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The Libtayo 700 mg every six-week option is already approved in the EU after an initial 12 weeks as adjuvant treatment for adult CSCC patients at high risk of recurrence after surgery and radiation.

  60% confidence

• The European Commission is expected to make a final decision in the coming months, which would allow the dosing regimen to be applied across all six approved indications in the EU.

  60% confidence

• Oncology assets in clinical development comprise nearly half of Regeneron's pipeline, and Libtayo serves as the backbone of many investigational combinations.

  60% confidence

• The CHMP adopted a positive opinion recommending approval of an alternative dosing schedule for Libtayo across all approved indications.

  60% confidence

• The positive CHMP opinion is supported by comprehensive pharmacokinetic and pharmacodynamic modeling and simulation data, integrated with clinical safety and efficacy data from Libtayo's clinical development program.

  60% confidence

Cited in these Via News reports

• Cancer-drug approvals are stacking up in Q4 2026, but the AI promises and Summit's cash needs are what to check →